Expression of beta 1 integrins (very late antigens-4 and -5) on myeloma cells and clinical correlates in patients with multiple myeloma.
beta 1 Integrins are considered to be essential for the differentiation of bone-marrow B cells through an interaction with fibronectin-expressed bone-marrow stromal cells. The expression of very late antigens-4 (VLA-4) and -5 (VLA-5) by CD38bright bone-marrow cells in patients with multiple myeloma was measured by flow cytometry using specific monoclonal antibodies. The percentage of CD38bright bone-marrow cells appeared to correlated with that of bone-marrow plasma cells as judged by examination of bone-marrow smears (r = 0.911, P < 0.0001). Expression of VLA-4 and VLA-5 by CD38bright cells varied between patients, but the expression of VLA-4 was always equal to or greater than that of VLA-5. The ratio of VLA-4 to VLA-5 expression (VLA-4:VLA-5 ratio) was calculated and compared with the clinical features of the myeloma patients. A high VLA-4:VLA-5 ratio (> 2.0) was associated with the presence of plasmacytomas and urinary Bence-Jones protein was more common in this group. No other correlations between the clinical features of the disease and the expression of beta 1 integrins were found.
Nishinarita
S
S
First Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Shimada
H
H
Ito
T
T
Namiki
H
H
Kawahira
H
H
Sawada
U
U
Horie
T
T
D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000368:Aged; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000032:analysis / Q000096:biosynthesis; D001536:Bence Jones Protein / Q000652:urine; D001854:Bone Marrow Cells / Q000276:immunology / Q000473:pathology*; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D039041:Integrin alpha4beta1; D016023:Integrins / Q000032:analysis / Q000096:biosynthesis*; D008297:Male; D008562:Membrane Glycoproteins; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D009244:NAD+ Nucleosidase / Q000032:analysis / Q000096:biosynthesis; D009367:Neoplasm Staging; D010954:Plasmacytoma / Q000150:complications; D017469:Receptors, Fibronectin / Q000032:analysis / Q000096:biosynthesis*; D016201:Receptors, Lymphocyte Homing / Q000032:analysis / Q000096:biosynthesis*; D016029:Receptors, Very Late Antigen / Q000032:analysis / Q000096:biosynthesis*
D015703:Antigens, CD; D000943:Antigens, Differentiation; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D039041:Integrin alpha4beta1; D016023:Integrins; D008562:Membrane Glycoproteins; D017469:Receptors, Fibronectin; D016201:Receptors, Lymphocyte Homing; D016029:Receptors, Very Late Antigen; D001536:Bence Jones Protein; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1